Status:
RECRUITING
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Lead Sponsor:
French Africa Pediatric Oncology Group
Collaborating Sponsors:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Childhood ALL
Eligibility:
All Genders
Up to 18 years
Brief Summary
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater th...
Detailed Description
A few studies conducted in developing countries confirm that it is possible to significantly improve the prognosis of children with Acute Lymphoblastic Leukemia (ALL) provided that the centres can ben...
Eligibility Criteria
Inclusion
- Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
- \-
Exclusion
- ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Key Trial Info
Start Date :
November 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04794296
Start Date
November 15 2021
End Date
September 1 2030
Last Update
October 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Treichville à ABIDJAN
Abidjan, Côte d’Ivoire
2
CHU Donka 030 BP 554
Conakry, Guinea
3
Hôpital Aristide Le Dantec, Avenue Pasteur,
Dakar, Senegal, BP 3001